Search research articles
Contact Us
Filters
Showing results (71-80 of 86) with videos related to
Page
of 9
Sort By:
Journal of Viral Hepatitis
|
August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)
S D Shafran, D Shaw, M Charafeddine, et al.
Journal of Viral Hepatitis
|
November 21, 2017
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study
A Brown, C Hézode, E Zuckerman, et al.
Journal of Hepatology
|
October 30, 2001
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study
S Caronia, M F Bassendine, R Barry, et al.
Gut
|
December 14, 2004
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C
A K P Lim, S D Taylor-Robinson, N Patel, et al.
Journal of Hepatology
|
December 3, 2013
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial
D Shoeb, J Dearden, A Weatherall, et al.
Alimentary Pharmacology & Therapeutics
|
February 3, 2012
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
P Ramachandran, A Fraser, K Agarwal, et al.
The American Journal of Gastroenterology
|
August 17, 2004
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C
S D Sullivan, D M Jensen, D E Bernstein, et al.
HIV Medicine
|
February 27, 2016
Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign
C Orkin, S Flanagan, E Wallis, et al.
Alimentary Pharmacology & Therapeutics
|
November 29, 2017
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3
Z M Younossi, M Stepanova, I M Jacobson, et al.
Alimentary Pharmacology & Therapeutics
|
April 24, 2014
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy
M H Miller, K Agarwal, A Austin, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 86) with videos related to
Sort By:
Page
of 9
Journal of Viral Hepatitis
|
August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)
S D Shafran, D Shaw, M Charafeddine, et al.
Journal of Viral Hepatitis
|
November 21, 2017
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study
A Brown, C Hézode, E Zuckerman, et al.
Journal of Hepatology
|
October 30, 2001
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study
S Caronia, M F Bassendine, R Barry, et al.
Gut
|
December 14, 2004
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C
A K P Lim, S D Taylor-Robinson, N Patel, et al.
Journal of Hepatology
|
December 3, 2013
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial
D Shoeb, J Dearden, A Weatherall, et al.
Alimentary Pharmacology & Therapeutics
|
February 3, 2012
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
P Ramachandran, A Fraser, K Agarwal, et al.
The American Journal of Gastroenterology
|
August 17, 2004
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C
S D Sullivan, D M Jensen, D E Bernstein, et al.
HIV Medicine
|
February 27, 2016
Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign
C Orkin, S Flanagan, E Wallis, et al.
Alimentary Pharmacology & Therapeutics
|
November 29, 2017
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3
Z M Younossi, M Stepanova, I M Jacobson, et al.
Alimentary Pharmacology & Therapeutics
|
April 24, 2014
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy
M H Miller, K Agarwal, A Austin, et al.
Page
of 9